Evidence map›Paper›PMID 37019448›Full record

SynthesisBMJ (Clinical research ed.)2023

Dietary sugar consumption and health: umbrella review.

Yin Huang, Zeyu Chen, Bo Chen, Jinze Li, Xiang Yuan, Jin Li, Wen Wang, Tingting Dai, Hongying Chen, Yan Wang and 8 more

Open access · hybridAbstract readSystematic Review
In one paragraph

Synthesis in BMJ (Clinical research ed.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 191 papers, 42 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
191citing papers in PubMed, 42 pooled it
57.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

191 citing papers in PubMed, 42 syntheses or guidelines pooled it, 287 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Pooled it
  18. Pooled it
  19. Pooled it
  20. Pooled it

131 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 2 institutions in 2 countries.

Yin HuangDepartment of Urology/Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
Zeyu ChenDepartment of Urology/Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
Bo ChenDepartment of Urology/Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
Jinze LiDepartment of Urology/Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
Xiang YuanDepartment of Oncology, West China Hospital, Sichuan University, Chengdu, China.
Jin LiDepartment of Urology/Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
Wen WangChinese Evidence-based Medicine Center, West China Hospital, Sichuan University, Chengdu, China.
Tingting DaiDepartment of Clinical Nutrition, West China Hospital, Sichuan University, Chengdu, China.
Hongying ChenResearch Core Facility, West China Hospital, Sichuan University, Chengdu, China.
Yan WangResearch Core Facility, West China Hospital, Sichuan University, Chengdu, China.
Ruyi WangDepartment of Urology/Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
Puze WangDepartment of Urology/Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
Jianbing GuoDepartment of Urology/Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
Qiang DongDepartment of Urology/Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
Chengfei LiuDepartment of Urologic Surgery, UC Davis School of Medicine, Sacramento, CA, USA liuliangren@scu.edu.cn.
Qiang WeiDepartment of Urology/Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
Dehong CaoDepartment of Urology/Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
Liangren LiuDepartment of Urology/Institute of Urology, West China Hospital, Sichuan University, Chengdu, China liuliangren@scu.edu.cn.ORCID 0000-0001-7597-6241
Sichuan University · CNUniversity of California, Davis · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate the quality of evidence, potential biases, and validity of all available studies on dietary sugar consumption and health outcomes.

designUmbrella review of existing meta-analyses. DATA SOURCES: PubMed, Embase, Web of Science, Cochrane Database of Systematic Reviews, and hand searching of reference lists. INCLUSION CRITERIA: Systematic reviews and meta-analyses of randomised controlled trials, cohort studies, case-control studies, or cross sectional studies that evaluated the effect of dietary sugar consumption on any health outcomes in humans free from acute or chronic diseases.

resultsThe search identified 73 meta-analyses and 83 health outcomes from 8601 unique articles, including 74 unique outcomes in meta-analyses of observational studies and nine unique outcomes in meta-analyses of randomised controlled trials. Significant harmful associations between dietary sugar consumption and 18 endocrine/metabolic outcomes, 10 cardiovascular outcomes, seven cancer outcomes, and 10 other outcomes (neuropsychiatric, dental, hepatic, osteal, and allergic) were detected. Moderate quality evidence suggested that the highest versus lowest dietary sugar consumption was associated with increased body weight (sugar sweetened beverages) (class IV evidence) and ectopic fatty accumulation (added sugars) (class IV evidence). Low quality evidence indicated that each serving/week increment of sugar sweetened beverage consumption was associated with a 4% higher risk of gout (class III evidence) and each 250 mL/day increment of sugar sweetened beverage consumption was associated with a 17% and 4% higher risk of coronary heart disease (class II evidence) and all cause mortality (class III evidence), respectively. In addition, low quality evidence suggested that every 25 g/day increment of fructose consumption was associated with a 22% higher risk of pancreatic cancer (class III evidence).

conclusionsHigh dietary sugar consumption is generally more harmful than beneficial for health, especially in cardiometabolic disease. Reducing the consumption of free sugars or added sugars to below 25 g/day (approximately 6 teaspoons/day) and limiting the consumption of sugar sweetened beverages to less than one serving/week (approximately 200-355 mL/week) are recommended to reduce the adverse effect of sugars on health. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42022300982.

Indexed as

Dietary SugarsWeight GainBeveragesCross-Sectional StudiesHumansMeta-Analysis as TopicSugarsSystematic Reviews as TopicDietary SugarsSugars

Identifiers

PMID37019448
PMCPMC10074550
OpenAlexW4362636766

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.